ICER releases draft evidence report on gene therapies for haemophilia A and B

ICER

13 September 2022 - Registration now open for 20 September “Early Insights” webinar.

The ICER today released a Draft Evidence Report assessing the comparative clinical effectiveness and value of etranacogene dezaparvovec (CSL Behring) for haemophilia B.

Read ICER Announcement

Michael Wonder

Posted by:

Michael Wonder